Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tablet keep kidney patients out of the hospital?

NCT ID NCT05726526

Disease control Sponsor: University of Manitoba Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests a home monitoring system called VIEWER for people with advanced chronic kidney disease (stage 5) or end-stage renal disease. The system includes a tablet, blood pressure cuff, scale, oxygen monitor, and motion tracker. Researchers want to see if using this platform alongside usual care reduces emergency room visits and hospital stays. About 340 participants will be randomly assigned to use VIEWER or receive standard care only.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VIEWER virtual care platform (tablet, blood pressure cuff, scale, oxygen monitor, motion tracker)
What this could lead to
If successful, this could provide a way for people with advanced kidney disease to manage their health at home and avoid unnecessary hospital visits.
What could go wrong
This is a relatively small trial (340 people) testing a device, not a drug. The platform may not reduce hospital visits as hoped, and some patients may find the technology difficult to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 340 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \>18 years of age * Patient or primary caregiver can read and speak English * Patient or patients substitute decision maker is able to provide informed consent * Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.) * Have stage 5 CKD (2 measurements of eGFR \<15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation, or have \>40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation * Followed in a multidisciplinary CKD clinic Exclusion Criteria: * Inability of self or caregiver assisted self-monitoring using VIEWER

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease stage 5 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease stage 5 End-stage renal disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chronic Disease Innovation Centre, Seven Oaks Hospital

    RECRUITING

    Winnipeg, Manitoba, R2V 3M3, Canada

  • Health Sciences Centre

    RECRUITING

    Winnipeg, Manitoba, R3A 1R9, Canada

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 5W9, Canada

  • Scarborough Health Network - General Hospital

    RECRUITING

    Scarborough Village, Ontario, M1P 2V5, Canada

  • St. Boniface Hospital

    RECRUITING

    Winnipeg, Manitoba, R2H 2A6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.